Literature DB >> 21878674

Sox4 cooperates with PU.1 haploinsufficiency in murine myeloid leukemia.

Georg Aue1, Yang Du, Susan M Cleveland, Stephen B Smith, Utpal P Davé, Delong Liu, Marc A Weniger, Jean Yves Metais, Nancy A Jenkins, Neal G Copeland, Cynthia E Dunbar.   

Abstract

Cooperation of multiple mutations is thought to be required for cancer development. In previous studies, murine myeloid leukemias induced by transducing wild-type bone marrow progenitors with a SRY sex determining region Y-box 4 (Sox4)-expressing retrovirus frequently carried proviral insertions at Sfpi1, decreasing its mRNA levels, suggesting that reduced Sfpi1 expression cooperates with Sox4 in myeloid leukemia induction. In support of this hypothesis, we show here that mice receiving Sox4 virus-infected Sfpi1(ko/+) bone marrow progenitors developed myeloid leukemia with increased penetrance and shortened latency. Interestingly, Sox4 expression further decreased Sfpi1 transcription. Ectopic SOX4 expression reduced endogenous PU.1 mRNA levels in HL60 promyelocytes, and decreased Sfpi1 mRNA levels were also observed in the spleens of leukemic and preleukemic mice receiving Sox4 virus-infected wild-type bone marrow cells. In addition, Sox4 protein bound to a critical upstream regulatory element of Sfpi1 in ChIP assays. Such cooperation probably occurs in de novo human acute myeloid leukemias, as an analysis of 285 acute myeloid leukemia patient samples found a significant negative correlation between SOX4 and PU.1 expression. Our results establish a novel cooperation between Sox4 and reduced Sfpi1 expression in myeloid leukemia development and suggest that SOX4 could be an important new therapeutic target in human acute myeloid leukemia.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21878674      PMCID: PMC3208283          DOI: 10.1182/blood-2011-04-351528

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  41 in total

1.  Regulation of macrophage and neutrophil cell fates by the PU.1:C/EBPalpha ratio and granulocyte colony-stimulating factor.

Authors:  Richard Dahl; Jonathan C Walsh; David Lancki; Peter Laslo; Sangeeta R Iyer; Harinder Singh; M Celeste Simon
Journal:  Nat Immunol       Date:  2003-09-07       Impact factor: 25.606

2.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data.

Authors:  Rafael A Irizarry; Bridget Hobbs; Francois Collin; Yasmin D Beazer-Barclay; Kristen J Antonellis; Uwe Scherf; Terence P Speed
Journal:  Biostatistics       Date:  2003-04       Impact factor: 5.899

3.  The caM kinase, Pnck, is spatially and temporally regulated during murine mammary gland development and may identify an epithelial cell subtype involved in breast cancer.

Authors:  H P Gardner; S I Ha; C Reynolds; L A Chodosh
Journal:  Cancer Res       Date:  2000-10-01       Impact factor: 12.701

4.  Prognostically useful gene-expression profiles in acute myeloid leukemia.

Authors:  Peter J M Valk; Roel G W Verhaak; M Antoinette Beijen; Claudia A J Erpelinck; Sahar Barjesteh van Waalwijk van Doorn-Khosrovani; Judith M Boer; H Berna Beverloo; Michael J Moorhouse; Peter J van der Spek; Bob Löwenberg; Ruud Delwel
Journal:  N Engl J Med       Date:  2004-04-15       Impact factor: 91.245

5.  Molecular and immunological evaluation of the transcription factor SOX-4 as a lung tumor vaccine antigen.

Authors:  Rachel S Friedman; Chaitanya S Bangur; Eden J Zasloff; Liqun Fan; Tongtong Wang; Yoshihiro Watanabe; Michael Kalos
Journal:  J Immunol       Date:  2004-03-01       Impact factor: 5.422

6.  Heterozygous PU.1 mutations are associated with acute myeloid leukemia.

Authors:  Beatrice U Mueller; Thomas Pabst; Motomi Osato; Norio Asou; Lisa M Johansen; Mark D Minden; Gerhard Behre; Wolfgang Hiddemann; Yoshiaki Ito; Daniel G Tenen
Journal:  Blood       Date:  2002-08-01       Impact factor: 22.113

7.  Bethesda proposals for classification of nonlymphoid hematopoietic neoplasms in mice.

Authors:  Scott C Kogan; Jerrold M Ward; Miriam R Anver; Jules J Berman; Cory Brayton; Robert D Cardiff; John S Carter; Sherri de Coronado; James R Downing; Torgny N Fredrickson; Diana C Haines; Alan W Harris; Nancy Lee Harris; Hiroshi Hiai; Elaine S Jaffe; Ian C M MacLennan; Pier Paolo Pandolfi; Paul K Pattengale; Archibald S Perkins; R Mark Simpson; Mark S Tuttle; Joanne F Wong; Herbert C Morse
Journal:  Blood       Date:  2002-07-01       Impact factor: 22.113

8.  Heterozygous deletion of the PU.1 locus in human AML.

Authors:  Nicola Bonadies; Thomas Pabst; Beatrice U Mueller
Journal:  Blood       Date:  2009-11-04       Impact factor: 22.113

9.  Identification of differentially expressed and developmentally regulated genes in medulloblastoma using suppression subtraction hybridization.

Authors:  Naoki Yokota; Todd G Mainprize; Michael D Taylor; Tomohiko Kohata; Michael Loreto; Shigeo Ueda; Wieslaw Dura; Wiesia Grajkowska; John S Kuo; James T Rutka
Journal:  Oncogene       Date:  2004-04-22       Impact factor: 9.867

10.  The myeloid master regulator transcription factor PU.1 is inactivated by AML1-ETO in t(8;21) myeloid leukemia.

Authors:  Rajani K Vangala; Marion S Heiss-Neumann; Janki S Rangatia; Sheo M Singh; Claudia Schoch; Daniel G Tenen; Wolfgang Hiddemann; Gerhard Behre
Journal:  Blood       Date:  2002-08-29       Impact factor: 22.113

View more
  14 in total

1.  Sox4 cooperates with CREB in myeloid transformation.

Authors:  Salemiz Sandoval; Christina Kraus; Er-Chieh Cho; Michelle Cho; Juraj Bies; Elena Manara; Benedetta Accordi; Elliot M Landaw; Linda Wolff; Martina Pigazzi; Kathleen M Sakamoto
Journal:  Blood       Date:  2012-05-24       Impact factor: 22.113

2.  CITED2-mediated human hematopoietic stem cell maintenance is critical for acute myeloid leukemia.

Authors:  P M Korthuis; G Berger; B Bakker; M Rozenveld-Geugien; J Jaques; G de Haan; J J Schuringa; E Vellenga; H Schepers
Journal:  Leukemia       Date:  2014-09-03       Impact factor: 11.528

3.  Transcriptomic and genomic heterogeneity in blastic plasmacytoid dendritic cell neoplasms: from ontogeny to oncogenesis.

Authors:  Florian Renosi; Anne Roggy; Ambre Giguelay; Lou Soret; Pierre-Julien Viailly; Meyling Cheok; Sabeha Biichle; Fanny Angelot-Delettre; Vahid Asnafi; Elizabeth Macintyre; Sandrine Geffroy; Mary Callanan; Tony Petrella; Eric Deconinck; Etienne Daguindau; Véronique Harrivel; Sabrina Bouyer; Véronique Salaun; Pascale Saussoy; Jean Feuillard; Pascal Fuseau; Philippe Saas; Olivier Adotévi; Fabrice Jardin; Christophe Ferrand; Claude Preudhomme; Jacques Colinge; Christophe Roumier; Francine Garnache-Ottou
Journal:  Blood Adv       Date:  2021-03-09

4.  PML-RARα co-operates with Sox4 in acute myeloid leukemia development in mice.

Authors:  Nader Omidvar; Mei Lin Maunakea; Letetia Jones; Sabina Sevcikova; Bin Yin; Karen L Himmel; Thelma R Tennant; Michelle M Le Beau; David A Largaespada; Scott C Kogan
Journal:  Haematologica       Date:  2012-11-09       Impact factor: 9.941

5.  The Sox4/Tcf7l1 axis promotes progression of BCR-ABL-positive acute lymphoblastic leukemia.

Authors:  Haiqing Ma; Saradhi Mallampati; Yue Lu; Baohua Sun; Enze Wang; Xiaohong Leng; Yun Gong; Haifa Shen; C Cameron Yin; Dan Jones; Hesham M Amin; M James You; Patrick Zweidler-McKay; Yupo Ma; Hagop M Kantarjian; Ralph B Arlinghaus; Armand Glassman; Xiaoping Sun
Journal:  Haematologica       Date:  2014-07-04       Impact factor: 9.941

6.  SOX4 enables oncogenic survival signals in acute lymphoblastic leukemia.

Authors:  Parham Ramezani-Rad; Huimin Geng; Christian Hurtz; Lai N Chan; Zhengshan Chen; Hassan Jumaa; Ari Melnick; Elisabeth Paietta; William L Carroll; Cheryl L Willman; Véronique Lefebvre; Markus Müschen
Journal:  Blood       Date:  2012-11-14       Impact factor: 22.113

Review 7.  Pleiotropic function of SRY-related HMG box transcription factor 4 in regulation of tumorigenesis.

Authors:  Seyed Mehdi Jafarnejad; Gholamreza Safaee Ardekani; Mazyar Ghaffari; Gang Li
Journal:  Cell Mol Life Sci       Date:  2012-10-19       Impact factor: 9.261

8.  Proteasome functioning in breast cancer: connection with clinical-pathological factors.

Authors:  Elena E Shashova; Yulia V Lyupina; Svetlana A Glushchenko; Elena M Slonimskaya; Olga V Savenkova; Alexey M Kulikov; Nikolay G Gornostaev; Irina V Kondakova; Natalia P Sharova
Journal:  PLoS One       Date:  2014-10-17       Impact factor: 3.240

9.  Sox4 links tumor suppression to accelerated aging in mice by modulating stem cell activation.

Authors:  Miguel Foronda; Paula Martínez; Stefan Schoeftner; Gonzalo Gómez-López; Ralph Schneider; Juana M Flores; David G Pisano; Maria A Blasco
Journal:  Cell Rep       Date:  2014-07-17       Impact factor: 9.423

10.  A novel PAD4/SOX4/PU.1 signaling pathway is involved in the committed differentiation of acute promyelocytic leukemia cells into granulocytic cells.

Authors:  Guanhua Song; Lulu Shi; Yuqi Guo; Linchang Yu; Lin Wang; Xiaoyu Zhang; Lianlian Li; Yang Han; Xia Ren; Qiang Guo; Kehong Bi; Guosheng Jiang
Journal:  Oncotarget       Date:  2016-01-19
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.